Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Jiangsu Sihuan Bioengineering Co., Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥2.22 |
52 Week High | CN¥4.57 |
52 Week Low | CN¥1.72 |
Beta | 0.54 |
1 Month Change | -3.06% |
3 Month Change | -8.64% |
1 Year Change | -18.38% |
3 Year Change | -43.80% |
5 Year Change | -31.06% |
Change since IPO | 249.38% |
Recent News & Updates
More Unpleasant Surprises Could Be In Store For Jiangsu Sihuan Bioengineering Co., Ltd's (SZSE:000518) Shares After Tumbling 26%
Apr 17Jiangsu Sihuan Bioengineering Co., Ltd (SZSE:000518) Investors Are Less Pessimistic Than Expected
Feb 26Shareholder Returns
518 | CN Biotechs | CN Market | |
---|---|---|---|
7D | -3.9% | -1.9% | -1.5% |
1Y | -18.4% | -20.1% | -11.8% |
Return vs Industry: 000518 exceeded the CN Biotechs industry which returned -20.1% over the past year.
Return vs Market: 000518 underperformed the CN Market which returned -11.8% over the past year.
Price Volatility
518 volatility | |
---|---|
518 Average Weekly Movement | 8.1% |
Biotechs Industry Average Movement | 6.1% |
Market Average Movement | 6.6% |
10% most volatile stocks in CN Market | 10.0% |
10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 000518's share price has been volatile over the past 3 months.
Volatility Over Time: 000518's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | 282 | Yu Guo | www.000518shsw.com/shsw |
Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers delusen, an anti-tumor biotherapeutic drug for the treatment of kidney cancer, malignant melanoma, and cancerous chest and abdominal mass; Xinde Lusheng; Xin Lisheng; and Ring BO. It also engages in breeding and sales of flowers and seedlings; and landscaping projects.
Jiangsu Sihuan Bioengineering Co., Ltd Fundamentals Summary
518 fundamental statistics | |
---|---|
Market cap | CN¥2.29b |
Earnings (TTM) | -CN¥59.28m |
Revenue (TTM) | CN¥234.80m |
9.7x
P/S Ratio-38.6x
P/E RatioIs 518 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
518 income statement (TTM) | |
---|---|
Revenue | CN¥234.80m |
Cost of Revenue | CN¥86.06m |
Gross Profit | CN¥148.75m |
Other Expenses | CN¥208.03m |
Earnings | -CN¥59.28m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.058 |
Gross Margin | 63.35% |
Net Profit Margin | -25.25% |
Debt/Equity Ratio | 3.1% |
How did 518 perform over the long term?
See historical performance and comparison